

Decision of the Governing Board of the Innovative Medicines Initiative 2 Joint Undertaking

Adopting the IMI2 JU Anti-Fraud Strategy

THE GOVERNING BOARD OF THE INNOVATIVE MEDICINES INITIATIVE 2 JOINT UNDERTAKING (IMI2 JU),

Having regard to Council Regulation (EU) No 557/2014 of 6 May 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking and in particular Article 14 thereof,

Having regard to the Statutes annexed to Council Regulation (EU) No 557/2014 and in particular Article 7(3)(r) thereof,

Having regard to the IMI2 JU Financial Rules¹ and in particular Articles 11, 12(2)(d), 16.1 (Paragraph 2), 21 (2), 23 and 50 thereof,

Whereas:

- (1) The IMI2 JU has implemented appropriate controls and procedures to combat fraud in accordance with the applicable rules and the Anti-Fraud Strategies applied by the Commission and by the Common Research Family.
- (2) The implementation of the Horizon 2020 Programme has led to a review of the Common Research Family Anti-fraud Strategy.
- (3) The IMI2 JU should align its Anti-Fraud Strategy with that of the other entities of the Research Family.
- (4) The revised Anti-Fraud Strategy should be adopted by the Governing Board,

HAS DECIDED AS FOLLOWS:

Article 1

The "IMI2 JU Anti-Fraud Strategy 2020 / 2024 Implementing the Common Research Family Anti-Fraud Strategy (RAFS)" annexed to this Decision shall replace the IMI2 JU Anti-Fraud Strategy annexed to the Decision of the IMI2 Governing Board No IMI2-GB-DEC-2015-30.

Article 2

This decision shall enter into force on the day following its adoption by the Governing Board of the IMI2 JU.

Brussels, on 27/4 2020,



Irene Norstedt
Chair of the IMI2 JU Governing Board

Annex: IMI2 JU Anti-Fraud Strategy 2020 / 2024 Implementing the Common Research Family Anti-Fraud Strategy (RAFS)

¹ Governing Board Decision No IMI2-GB-2015-44 of 22 December 2015.

